Ultrasound study reveals how fasting and tirzepatide pause impact stomach retention
NCT ID NCT07299084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how long you need to fast and how stopping the diabetes/weight-loss drug tirzepatide changes the amount of food left in your stomach after a meal. Researchers will use ultrasound to check stomach contents in 40 people with type 2 diabetes or obesity. The goal is to better understand stomach emptying, which can affect safety before procedures like surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?